Vertice Pharma Appoints Scott Meyers As Chief Operating Officer

BERKELEY HEIGHTS, N.J., Feb. 22, 2016 /PRNewswire/ -- Vertice Pharma today announced the appointment of Scott Meyers as Chief Operating Officer. 

"We are pleased to welcome Scott to the Vertice Pharma leadership team. Scott brings over 15 years of progressive leadership experience and a strong track record of driving top tier performance. I am confident that Scott will provide immediate leadership and focus to a range of initiatives which will support our growth strategy," said Don DeGolyer, President & Chief Executive Officer of Vertice Pharma.

"I am delighted to have the opportunity to join a talented leadership team at Vertice Pharma with their commitment to people, customers and growth," said Mr. Meyers.

Most recently, Scott has served as Vice President and General Manager, Dermatology of Fougera Inc., (a Sandoz / Novartis company). Prior to it, Scott led Strategic Planning & Market Analytics for Sandoz US and worked at McKinsey & Company's pharmaceutical practice in New Jersey, focusing on R&D and commercial operations.  Scott also worked as a Chemical Engineer for Merck at their West Point, PA.

Scott holds a Master of Business Administration from Northwestern University's Kellogg School of Management and holds a Master of Chemical Engineering, a Bachelor of Science in Chemical Engineering, and a Bachelor of Arts in Chemistry all from Cornell University.

About Vertice Pharma

Vertice Pharma is a specialty pharmaceuticals company focused on improving patients' health. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies.  Vertice Pharma has global headquarters in the United Kingdom and United States headquarters in New Jersey.

For more information visit

Media Contact:
Vertice Pharma
Kellen Johnson  - [email protected]

To view the original version on PR Newswire, visit:

SOURCE Vertice Pharma

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.